Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare To Track Transfusions In Dialysis Patients To Ensure Appropriate ESA Use

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS proposes to monitor transfusions in patients with end-stage renal disease as a new Medicare quality measure aimed at ensuring erythropoiesis-stimulating agents like Amgen’s Epogen are not “underutilized.”

You may also be interested in...



ESAs And Transfusions In Dialysis Patients: Watching For The Tipping Point

A study from the U.S. Renal Data System contributes to concerns that decreasing use of erythropoiesis-stimulating agents like Amgen’s Epogen in dialysis patients can lead to a significant increase in the need for blood transfusions.

As COVID Vaccine Market Goes Private, US Government Can Still Help Firms Boost Sales

Pfizer and Moderna’s ‘endemic’ COVID vaccine market scenarios anticipate much higher booster rates than have been achieved so far, but performance for 2023 may be aided by the Biden Administration campaign to increase shots this winter.

CMS-Manufacturer Discussion Of Medicare Price Negotiation Program Scheduled For 13 December

Agency reaches out to manufacturers as it develops its approach to implementing the controversial new program.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel